Abcam, ab250111, Anti-GANAB antibody [EPR12377(B)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal GANAB antibody. Carrier free. Suitable for IP, WB, Flow Cyt (Intra) and reacts with Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR12377(B),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse, Rat,
Applications:WB, IP, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250111 is the carrier-free version of
ab179805
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
GANAB also known as Glucosidase II alpha subunit or neutral alpha-glucosidase AB is an enzyme with an approximate mass of 110 kDa. It functions as part of the endoplasmic reticulum's quality control system modifying N-linked glycans on newly synthesized glycoproteins. GANAB cleaves glucose residues facilitating proper folding and maturation of glycoproteins. Expression of GANAB occurs mainly in the endoplasmic reticulum of various cell types indicating its broad relevance in cellular protein processing.
Biological function summary
GANAB performs a critical role in the maintenance of glycoprotein quality. It acts as part of the Glucosidase II complex working alongside a beta subunit to continue glycoprotein processing. Through the removal of glucose from N-glycans GANAB aids in the correct protein folding and prevents accumulation of misfolded proteins. This function is essential for the normal function of the endoplasmic reticulum-associated degradation (ERAD) pathway.
Pathways
Proper glycoprotein folding through GANAB activity integrates into the broader ERAD pathway and the unfolded protein response. GANAB's role complements the activities of other glycosylation-related proteins such as calnexin and calreticulin ensuring only correctly folded proteins advance through the secretory pathway. This integrated network maintains cellular homeostasis and prevents stress conditions in the endoplasmic reticulum.
GANAB's dysfunction associates with autosomal dominant polycystic liver disease and familial hyperinsulinism. These connections emphasize the importance of proper glycoprotein modification managed by GANAB. In these conditions alterations in GANAB or its interacting proteins can lead to aberrant cellular functions and consequent pathologies highlighting potential therapeutic targets in GANAB-associated pathways for disease management.